LONG-TERM EFFICACY AND SAFETY OF PONATINIB IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 4-YEAR RESULTS FROM THE PIVOTAL PHASE 2 PACE TRIAL

Autor: Cortes, JE, Pinilla-Ibarz, J, Le Coutre, PD, Paquette, R, Chuah, C, Nicolini, FE, Apperley, JF, Khoury, HJ, Talpaz, M, Baccarani, M, Lustgarten, S, Haluska, FG, Guilhot, F, Deininger, MW, Hochhaus, A, Hughes, TP, Shah, NP, Kantarjian, HM

Publikováno v: 21st Congress of the European Hematology Association

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::a19a096480f8c3953e7ffeccf0d9d2ed
http://hdl.handle.net/10044/1/40379

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Autor: Cortes, JE, Kim, D-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, FE, Apperley, JF, Khoury, HJ, Talpaz, M, DiPersio, J, DeAngelo, DJ, Abruzzese, E, Rea, D, Baccarani, M, Müller, MC, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, VM, Clackson, T, Turner, CD, Haluska, FG, Guilhot, F, Deininger, MW, Hochhaus, A, Hughes, T, Goldman, JM, Shah, NP, Kantarjian, H, PACE Investigators

Publikováno v: The New England journal of medicine, vol 369, iss 19

BackgroundPonatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::7cc75f7e4e51a4a96142790ddee69076
https://escholarship.org/uc/item/6s61b8vf

Identification of kinase inhibitors as potential host-directed therapies for intracellular bacteria.

Autor: van den Biggelaar, Robin H. G. A.^1,2 (AUTHOR) r.h.g.a.van_den_biggelaar@lumc.nl, Walburg, Kimberley V.¹ (AUTHOR), van den Eeden, Susan J. F.¹ (AUTHOR), van Doorn, Cassandra L. R.¹ (AUTHOR), Meiler, Eugenia³ (AUTHOR), de Ries, Alex S.² (AUTHOR), Fusco, M. Chiara² (AUTHOR), Meijer, Annemarie H.² (AUTHOR), Ottenhoff, Tom H. M.¹ (AUTHOR), Saris, Anno¹ (AUTHOR) a.saris@lumc.nl

Publikováno v: Scientific Reports. 7/26/2024, Vol. 14 Issue 1, p1-16. 16p.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Autor: Cortes JE; The University of Texas MD Anderson Cancer Center, Houston, TX., Kim DW; Seoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea., Pinilla-Ibarz J; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL., le Coutre PD; Charité, Universitätsmedizin Berlin, Berlin, Germany., Paquette R; Cedars-Sinai Medical Center, Los Angeles, CA., Chuah C; Singapore General Hospital, Duke-National University of Singapore (NUS) Medical School, Singapore., Nicolini FE; Centre Hospitalier Lyon-Sud, Pierre-Bénite, Lyon, France., Apperley JF; Centre for Haematology, Imperial College, London, United Kingdom., Khoury HJ; Winship Cancer Institute of Emory University, Atlanta, GA., Talpaz M; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI., DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA., Abruzzese E; S. Eugenio Hospital, Tor Vergata University, Rome, Italy., Rea D; Service d'Hématologie Adulte et Centre d'Investigation Clinique, Hôpital Saint Louis, Paris, France., Baccarani M; Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy., Müller MC; III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany., Gambacorti-Passerini C; University of Milano-Bicocca/San Gerardo Hospital, Monza, Italy., Lustgarten S; ARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Rivera VM; ARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Haluska FG; ARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Guilhot F; Centre d'Investigation Clinique (CIC) 1402, INSERM, Poitiers, France.; Centre Hospitalier Universitaire de Poitiers, Poitiers, France., Deininger MW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Hochhaus A; Hematology/Oncology, Jena University Hospital, Jena, Germany., Hughes TP; University of Adelaide/South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia; and., Shah NP; Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston, TX.

Publikováno v: Blood [Blood] 2018 Jul 26; Vol. 132 (4), pp. 393-404. Date of Electronic Publication: 2018 Mar 22.

Role of STING in the treatment of non-small cell lung cancer.

Autor: Tang, Wenhua¹ (AUTHOR), Zhou, Wenjie¹ (AUTHOR), Ji, Mei¹ (AUTHOR), Yang, Xin¹ (AUTHOR) yangxindoctor@163.com

Publikováno v: Cell Communication & Signaling. 4/2/2024, Vol. 22 Issue 1, p1-15. 15p.